Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2010

01-07-2010 | Epidemiology

Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis

Authors: Yun Chen, Jianping Pei

Published in: Breast Cancer Research and Treatment | Issue 2/2010

Login to get access

Abstract

A number of studies have been investigated the association between CYP17 T34C polymorphism and the risk of breast cancer; the results of these studies are inconsistent, however. This fact implies that the effect of CYP17 T34C polymorphism on susceptibility to breast cancer may be modified by other risk factors. In order to provide a more definitive conclusion, a full meta-analysis combining and summarizing 24 studies was first performed. Both traditional method and Bayesian approach were applied. Odds ratio was estimated using a dominant mode of inheritance after a biological justification for the choice of genetic model. The results of homogeneity analysis (H = 1.16, I 2 = 25.4%, and P = 0.127) suggested the presence of heterogeneity across the studies. Thus, random effects models simulated by the DerSimonian–Laird method were employed. The capability of a Bayesian approach was highlighted in the estimation of a pooled odds ratio and 95% confidence interval. The results of meta-analysis (OR = 1.001, CI = 0.832–1.208) suggest no significant association in the combined populations. Furthermore, Bayesian meta-regression and subgroup analysis were conducted to investigate the sources of heterogeneity. The risk factors evaluated in the study were menopausal status, ethnicity, age at menarche, age at first birth, parity, use of oral contraceptives, body mass index (BMI), and use of hormone repair therapy (HRT). After these population stratifications, there was evidence indicating that a possible impact of menopausal status, age at menarche, and BMI on the association between CYP17 T34C polymorphism and the risk of breast cancer.
Appendix
Available only for authorised users
Literature
1.
Kristensen VN, Borresen-Dale AL (2000) Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res 462:323–333CrossRefPubMed
2.
Thompson PA, Ambrosone C (2000) Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 27:125–134CrossRefPubMed
3.
Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689CrossRefPubMedPubMedCentral
4.
Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomark Prev 8:741–747
5.
Bennett IC, Gattas M, Teh BT (1999) The genetic basis of breast cancer and its clinical implications. Aust N Z J Surg 69:95–105CrossRefPubMed
6.
Johnson-Thompson MC, Guthrie J (2000) Ongoing research to identify environmental risk factors in breast carcinoma. Cancer 88:1224–1229CrossRefPubMed
7.
Picado-Leonard J, Miller WL (1987) Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-hydroxylase/17, 20 lyase): similarity with the gene for P450c21. DNA 6:439–448CrossRefPubMed
8.
Miller WL (1998) Early steps in androgen biosynthesis: from cholesterol to DHEA. Baillieres Clin Endocrinol Metab 12:67–81CrossRefPubMed
9.
Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P et al (1994) Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873–1876CrossRefPubMed
10.
Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE (1997) A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063–1065PubMed
11.
Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE (1998) Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 58:585–587PubMed
12.
Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL et al (1998) No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 77:2045–2047CrossRefPubMedPubMedCentral
13.
Helzlsouer KJ, Huang HY, Strickland PT, Hoffman S, Alberg AJ, Comstock GW, Bell DA (1998) Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomark Prev 7:945–949
14.
Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS (1998) CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomark Prev 7:941–944
15.
Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE et al (1999) The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 59:1015–1020PubMed
16.
Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY (1999) Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 59:4870–4875PubMed
17.
Hamajima N, Iwata H, Obata Y, Matsuo K, Mizutani M, Iwase T et al (2000) No association of the 5′ promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 91:880–885CrossRefPubMed
18.
Kuligina ES, Togo AV, Suspitsin EN, Grigoriev MY, Pozharisskiy KM, Chagunava OL et al (2000) CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett 156:45–50CrossRefPubMed
19.
Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S et al (2000) Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomark Prev 9:1343–1348
20.
Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE (2001) Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61:785–789PubMed
21.
Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S et al (2003) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 5:R45–R51CrossRefPubMedPubMedCentral
22.
Gudmundsdottir K, Thorlacius S, Jonasson JG, Sigfusson BF, Tryggvadottir L, Eyfjord JE (2003) CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status. Br J Cancer 88:933–936CrossRefPubMedPubMedCentral
23.
Wu AH, Seow A, Arakawa K, Van Den Berg D, Lee HP, Yu MC (2003) HSD17B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 104:450–457CrossRefPubMed
24.
Chacko P, Rajan B, Mathew BS, Joseph T, Pillai MR (2004) CYP17 and SULT1A1 gene polymorphisms in Indian breast cancer. Breast Cancer 11:380–388CrossRefPubMed
25.
Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G et al (2004) Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 101:264–269CrossRefPubMed
26.
Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL et al (2005) CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study. Breast Cancer Res 7:R513–R521CrossRefPubMedPubMedCentral
27.
Shin MH, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY et al (2005) Genetic polymorphism of CYP17 and breast cancer risk in Korean women. Exp Mol Med 37:11–17CrossRefPubMed
28.
Han DF, Zhou X, Hu MB, Xie W, Mao ZF, Chen DE et al (2005) Polymorphisms of estrogen-metabolizing genes and breast cancer risk: a multigenic study. Chin Med J 118:1507–1516PubMed
29.
Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S (2007) CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet 52:159–165CrossRefPubMed
30.
Chen Y, Gammon MD, Teitelbaum SL, Britton JA, Terry MB, Shantakumar S et al (2008) Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project. Carcinogenesis 29:766–771CrossRefPubMed
31.
Samson M, Rama R, Swaminathan R, Sridevi V, Nancy KN, Rajkumar T (2009) CYP17 (T34C), CYP19 (Trp39Arg), and FGFR2 (C906T) polymorphisms and the risk of breast cancer in south Indian women. Asian Pac J Cancer Prev 10:111–114PubMed
32.
Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K (2009) Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat 114:327–338CrossRefPubMed
33.
Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 8:843–854
34.
Ye Z, Parry JM (2002) The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17:119–126CrossRefPubMed
35.
Feigelson HS, McKean-Cowdin R, Henderson BE (2002) Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17:445–446 (author reply 7–8)CrossRefPubMed
36.
Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR et al (2000) CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 92:1674–1681CrossRefPubMed
37.
Bergman-Jungestrom M, Gentile M, Lundin AC, Wingren S (1999) Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer 84:350–353CrossRefPubMed
38.
Chen Y, Pei J (2009) An assessment of a TNF polymorphic marker for the risk of HCV infection: meta-analysis and a new clinical study design. Infect Genet Evol 9:1356–1363CrossRefPubMed
39.
Baker WL, White CM, Cappelleri JC, Kluger J, Coleman CI (2009) Understanding heterogeneity in meta-analysis: the role of meta-regression. Int J Clin Pract 63:1426–1434CrossRefPubMed
40.
Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crino L et al (2009) CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case–control study. BMC Cancer 9:115CrossRefPubMedPubMedCentral
41.
Attia J, Thakkinstian A, D’Este C (2003) Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 56:297–303CrossRefPubMed
42.
Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2005) The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 34:1319–1328CrossRefPubMed
43.
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558CrossRefPubMed
44.
45.
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed
46.
Carlin BP, Galfand AE, Smith AFM (1992) Hierarchical Bayesian analysis of changepoint problems. Appl Stat 41:389–408CrossRef
47.
Breslow NE, Clayton DG (1993) Approximate inference in generalized linear mixed models. J Am Stat Assoc 88:9–25
48.
Boston RC, Sumner AE (2003) STATA: a statistical analysis system for examining biomedical data. Adv Exp Med Biol 537:353–369CrossRefPubMed
49.
DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114CrossRefPubMed
50.
Spiegelhalter D, Thomas A, Best N, Lunn D (2003) Winbugs user manual. MRC Biostatistics Unit, Cambridge
51.
Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J (2006) CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans. J Nutr 136:1596–1603PubMed
52.
Verla-Tebit E, Wang-Gohrke S, Chang-Claude J (2005) CYP17 5′-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study. Breast Cancer Res 7:R455–R464CrossRefPubMedPubMedCentral
53.
Einarsdottir K, Rylander-Rudqvist T, Humphreys K, Ahlberg S, Jonasdottir G, Weiderpass E et al (2005) CYP17 gene polymorphism in relation to breast cancer risk: a case-control study. Breast Cancer Res 7:R890–R896CrossRefPubMedPubMedCentral
54.
Young IE, Kurian KM, Annink C, Kunkler IH, Anderson VA, Cohen BB et al (1999) A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer 81:141–143CrossRefPubMedPubMedCentral
55.
Spicer DV, Pike MC (1994) Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr 16:139–147PubMed
56.
Salanti G, Sanderson S, Higgins JP (2005) Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med 7:13–20CrossRefPubMed
57.
58.
van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21:589–624CrossRefPubMed
59.
60.
Tran BN, Nguyen ND, Eisman JA, Nguyen TV (2008) Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis. BMC Med Genet 9:55CrossRefPubMedPubMedCentral
61.
Bernstein L, Pike MC, Ross RK, Henderson BE (1991) Age at menarche and estrogen concentrations of adult women. Cancer Causes Control 2:221–225CrossRefPubMed
62.
Goodman MT, McDuffie K, Guo C, Terada K, Donlon TA (2001) CYP17 genotype and ovarian cancer: a null case-control study. Cancer Epidemiol Biomark Prev 10:563–564
63.
Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomark Prev 14:815–820CrossRef
64.
Butt S, Borgquist S, Anagnostaki L, Landberg G, Manjer J (2009) Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. Int J Cancer 125:1926–1934CrossRefPubMed
65.
Metadata
Title
Factors influencing the association between CYP17 T34C polymorphism and the risk of breast cancer: meta-regression and subgroup analysis
Authors
Yun Chen
Jianping Pei
Publication date
01-07-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0690-9

Other articles of this Issue 2/2010

Breast Cancer Research and Treatment 2/2010 Go to the issue

Preclinical study

Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody

Preclinical study

Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer

Preclinical study

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

Preclinical study

RETRACTED ARTICLE: FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors

Epidemiology

Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects

Brief Report

Two founder BRCA2 mutations predispose to breast cancer in young women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits